anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to a method of manufacturing a non-irritating natural mask pack for skin care. The method of manufacturing a non-irritating natural mask pack for skin care comprises the following steps: preparing a Broussonetia kazinoki SIEB. raw material; preparing a Hibiscus manihot Extract; preparing a Broussonetia kazinoki SIEB. fiber mixture; preparing a cosmetic additive mixture; preparing a first pack mixture; preparing a second pack mixture; and rapid freeze-drying. The non-irritating natural mask pack of the present invention uses natural ingredients, and thus does not cause skin trouble or irritation. Furthermore, the non-irritating natural mask pack has excellent hygroscopicity, deodorization, and air permeability by effectively depositing various cosmetic ingredients.
Low-level light therapy (LLLT) is a treatment for meibomian gland dysfunction. The proposed mechanism of action is photobiomodulation of cells leading to improved adenosine triphosphate synthesis, reduction of reactive oxygen species in oxidatively-stressed cells, and the activation of transcription factors involved in cellular proliferation, migration and survival. Understanding of how low-level light therapy based therapy alters meibomian gland function is poor. This study will examine the effect of low-level light therapy on individuals with meibomian gland dysfunction. Eligible subjects will receive 15 minutes of low-level light therapy per week over a 3 week period. Meibum collected prior to treatment will be compared to meibum collected after 3 treatment sessions for alteration in protein and lipid composition.
Dysmenorrhea, characterized by pain and related symptoms, significantly impacts women's quality of life in work and education, prompting a comprehensive evaluation of associated factors. The objective of this study was to utilize structural equation modeling (SEM) to analyze and assess the biopsychosocial factors influencing dysmenorrhea among university students. Three hundred and thirty-nine university students were included in this cross-sectional descriptive study. Data were collected using the Participant Information Form, the Beck Anxiety Scale (BAS), the Beck Depression Scale (BDS), the Multidimensional Scale of Perceived Social Support (MSPSS), the Adverse Childhood Experiences Scale (ACES), the Pain Catastrophizing Scale (PCS) and the Visual Analogue Scale (VAS). It was determined that the variables of pain onset (t = 3.24, p < .05) and age at menarche (t = -2.16, p < .05) showed a significant relationship with the model. The variables of the PCS (t = 16.87, p < .001), BDS (t = 3.06, p < .05), and BAS (t = 5.13, p < .001) showed a significant relationship with the model. Social factors in the model were examined, and a family history of dysmenorrhea and the ACES variables did not contribute significantly to the model (p > .05). The study indicates primary dysmenorrhea influenced by biological and psychological factors. Nurses should conduct holistic assessments and provide comprehensive care for affected women.
The possibility of iatrogenic overdosage can be minimized by carefully monitoring muscle twitch response to peripheral nerve stimulation.   
  
Excessive doses of vecuronium produce enhanced pharmacological effects. Residual neuromuscular blockade beyond the time period needed may occur with vecuronium as with other neuromuscular blockers. This may be manifested by skeletal muscle weakness, decreased respiratory reserve, low tidal volume, or apnea. A peripheral nerve stimulator may be used to assess the degree of residual neuromuscular blockade from other causes of decreased respiratory reserve.   
  
Respiratory depression may be due either wholly or in part to other drugs used during the conduct of general anesthesia such as narcotics, thiobarbiturates and other central nervous system depressants.   
  
Under such circumstances the primary treatment is maintenance of a patent airway and manual or mechanical ventilation until complete recovery of normal respiration is assured. Pyridostigmine, neostigmine, or edrophonium, in conjunction with atropine or glycopyrrolate will usually antagonize the skeletal muscle relaxant action of vecuronium. Satisfactory reversal can be judged by adequacy of skeletal muscle tone and by adequacy of respiration. A peripheral nerve stimulator may also be used to monitor restoration of twitch height. Failure of prompt reversal (within 30 minutes) may occur in the presence of extreme debilitation, carcinomatosis, and with concomitant use of certain broad spectrum antibiotics, or anesthetic agents and other drugs which enhance neuromuscular blockade or cause respiratory depression of their own. Under such circumstances the management is the same as that of prolonged neuromuscular blockade. Ventilation must be supported by artificial means until the patient has resumed control of his respiration. Prior to the use of reversal agents, reference should be made to the specific package insert of the reversal agent. The effects of hemodialysis and peritoneal dialysis on plasma levels of vecuronium and its metabolite are unknown.
Techniques are disclosed herein for generating personalized nutritional recommendations for foods available from one or more food sources. Using the technologies described herein, a programmatic analysis is performed on different data to predict values of personalized nutrition data, such as one or more target biomarkers,that are associated with an individual after eating the foods. Personalized nutritional recommendations for foods available from the food sources are then generated, using the predicted values, and provided to the individual. The predictions are based on data that is associated with the individual, such as microbiome data, triglycerides data, glucose data, nutritional data, questionnaire data, and the like. A prediction service can utilize a machine learning mechanism to generate the predicted personalized nutrition data. A nutrition service utilizes the predicted personalized nutrition data when generating the personalized nutritional recommendations.
The invention relates to the technical field of a traditional Chinese medicine preparation, and discloses a traditional Chinese medicine enema for treating exogenous fever of infants. The enema is prepared by taking radix scutellariae, honeysuckle, forsythia, dandelion, gypsum and rhizoma anemarrhenae as raw materials through the steps of soaking, decocting and filtering. The invention is characterized in that each dose of enema is prepared from the following raw materials in proportioning by weight: 2-5g of radix scutellariae, 5-8g of honeysuckle, 2-5g of forsythia, 5-8g of dandelion, 9-12g of gypsum and 2-5g of rhizoma anemarrhenae. The enema has the functions of clearing away heat and toxic material, diminishing inflammation and allaying the fever, and is a preferred medicament for allaying the exogenous fever of infants. Compared with the existing treatment method, the enema disclosed by the invention can be quickly absorbed through rectal administration, has a good treatment effect, reduces the 'first pass effect' of general medicaments, has high bioavailability and low price, is convenient and easy to implement, does not have toxic side effects, has an obvious effect on allaying the fever, and also solves the problem that infants are afraid of needles and medicaments. Observed by 200 clinical cases, the antipyretic effective rate within 36 hours is 100%.
The invention relates to a docetaxel injection. The docetaxel injection is prepared from docetaxel, lipoic acid, medicinal absolute ethyl alcohol and polyethylene glycol stearate. The lipoic acid is added into the docetaxel injection, and stability of double bonds in the docetaxel is facilitated. In addition, the lipoic acid has the anti-oxidation effect and can slow down product degradation. In the injection preparation process, compared with an existing technology, the medicinal absolute ethyl alcohol is not removed. During clinical use, the step of adding ethyl alcohol for dilution is omitted, and use is safer, more convenient and faster. The four components in the injection are compounded for use, the docetaxel injection meets the USP35 docetaxel injection standard within the two-year life time, and the clinical application is safer.
This group is similar to the TB I. However, we use the lesser contrast media in the second phase of injection. The second phase of contrast media injection is applied with a velocity of 3ml/s and the volume of the contrast media is 60ml minus the amount of first phase injection. The total volume of the contrast media is 70 ml, also including the 10ml for pre-diagnostic test bolus images. The following saline flush uses 30 ml of normal saline. The start time of the diagnostic scan is at the A second as well.
The study will be performed utilizing a prospective multi-center randomized model. Approximately 7 centers will be included in the study as listed above. Patients will be informed of clinical trial and asked if they would like to participate. Patients are informed that participation is optional. Patients may withdraw from study any time prior to or after surgery. Patients will be randomized 2:1 ratio endoscopic:open surgery. Both the endoscopic and open surgical techniques are utilized in standard of care. If a subject requires an open surgery approach (based on the surgeons assessment at the time of surgery pre or post incision) after they are randomized to the endoscopic arm, they will be switched to the open arm and included in the open crossover arm of the study.

Study procedures will occur at the following time points; Pre-op, 6 wk, 3 mon, 6 mon, 1 yr and 2 yr follow-up.Subjects will complete questionnaires that assess pain level and location, functional capacity, work and health status, medication usage and duration of symptoms.
The additive central-nervous-system effects of other drugs, such as phenothiazines, narcotic analgesics, barbiturates, antidepressants, scopolamine, and monoamine-oxidase inhibitors, should be borne in mind when these other drugs are used concomitantly with or during the period of recovery from lorazepam injection (see CLINICAL PHARMACOLOGY and WARNINGS).

Extreme caution must be used when administering lorazepam injection to elderly patients, very ill patients, or to patients with limited pulmonary reserve because of the possibility that hypoventilation and/or hypoxic cardiac arrest may occur. Resuscitative equipment for ventilatory support should be readily available (see WARNINGS and DOSAGE AND ADMINISTRATION).

When lorazepam injection is used intravenous as the premedicant prior to regional or local anesthesia, the possibility of excessive sleepiness or drowsiness may interfere with patient cooperation in determining levels of anesthesia. This is most likely to occur when greater than 0.05 mg/kg is given and when narcotic analgesics are used concomitantly with the recommended dose (see ADVERSE REACTIONS).

As with all benzodiazepines, paradoxical reactions may occur in rare instances and in an unpredictable fashion (see ADVERSE REACTIONS). In these instances, further use of the drug in these patients should be considered with caution.

There have been reports of possible propylene glycol toxicity (e.g., lactic acidosis, hyperosmolality, hypotension) and possible polyethylene glycol toxicity (e.g., acute tubular necrosis) during administration of Lorazepam injection at higher than recommended doses. Symptoms may be more likely to develop in patients with renal impairment.
PURPOSE:A healthy drink having effect of Cassia torosa Cav. and adlay as crude drugs and a taste like coffee, by using Cassia torosa Cav. and adlay as raw material. CONSTITUTION:A decocted extract of seed of Cassia torosa Cav. or powder of the extract is blended with a decocted extract of seed of adlay or powder of the extract in a weight ratio of (1-4):(4-1) to give a healthy drink, which may be preferably blended with an organic acid such as malic acid, citric acid, etc. dissolved in warm water to adjust the drink to 4.0-6.5pH.
In controlled clinical trials, clinically important changes in standard laboratory parameters were rarely associated with administration of irbesartan and hydrochlorothiazide tablets.

Creatinine, Blood Urea Nitrogen: Minor increases in blood urea nitrogen (BUN) or serum creatinine were observed in 2.3% and 1.1%, respectively, of patients with essential hypertension treated with irbesartan-hydrochlorothiazide alone. No patient discontinued taking irbesartan-hydrochlorothiazide due to increased BUN. One patient discontinued taking irbesartan and hydrochlorothiazide due to a minor increase in serum creatinine.

Liver Function Tests: Occasional elevations of liver enzymes and/or serum bilirubin have occurred. In patients with essential hypertension treated with irbesartan and hydrochlorothiazide alone, one patient was discontinued due to elevated liver enzymes.

Serum Electrolytes: [see Warnings and Precautions (5.2,5.6)].
This study will be a pilot randomized controlled trial on the efficacy of HRV biofeedback as adjunctive therapy to self-help CBT-I on insomnia. Potential participants will be recruited from the community through posters, social media sites and/or emails. Prior to all study procedures, the research purpose and data collection procedure will be given to the participants and an informed consent will be obtained from potential participants. Around 44 eligible participants will be randomly assigned to either self-help CBT-I with HRV biofeedback (combined group) or self-help CBT-I only group in a ratio of 1:1. The randomization will be performed by an independent assessor using a computer-generated list of numbers. No deception is necessary. Participants in combined group will receive a booklet with content related to both self-help CBT-I and HRV biofeedback based on guidelines of self-help CBT-I and protocol for HRV biofeedback training per week for 6 consecutive weeks. Participants are required to use around 1 hour to read through the content. The combined group is requested to perform the HRV biofeedback practice with a Bluetooth sensor connected with Inner Balance mobile application for around 20 minutes a day, 5-7 days a week and record their practice. Self-help CBT-I only group will receive a booklet with content related to self-help CBT-I only per week for 6 consecutive weeks. Participants are required to use 30 to 40 minutes to read through the content. The combined group and self-help CBT-I only group will complete a set of questionnaires and HRV measurement before the treatment commences, immediately after treatment, and 4 weeks after the treatment sessions are completed.
BACKGROUND AND AIMS: Chronic hepatitis B virus (HBV) infection is associated with a reduced risk of dyslipidaemia. Using a human faecal microbiota transplantation (FMT), we compared changes in gut microbiota and lipid profiles in mice transplanted with human faeces from HBV-infected and non-infected individuals.
APPROACH AND RESULTS: A total of 19 mice received human FMT from four HBV-infected individuals and were categorised into the HBV-positive mice group, while 20 mice received FMT from four HBV-non-infected individuals into the HBV-negative one. In the analysis of gut microbiota in FMT mice, we observed a robust increase in alpha diversity and abundance of Akkermansia muciniphila in HBV-positive mice, compared to that in HBV-negative. Functional inference analysis revealed that the pathways involved in glycerolipid metabolism were more enriched in HBV-positive mice. At 5 weeks of FMT, the reduced triglyceride (TG) level was predominantly observed in HBV-positive mice.
CONCLUSIONS: Altered gut microbiota accompanied by HBV infection was associated with a robust increase in alpha diversity and butyrate producers, which resulted in a reduced level of TG at 5 weeks post-FMT. This indicates that the reduced risk of dyslipidaemia in chronic HBV infection may be due to the altered gut microbiota accompanied by HBV infection.
High-fat diet (HFD) induced obesity is associated with depression-related behavioral and neurogenic changes and may lead to cognitive impairment. Fluoxetine (FXT), the most commonly used antidepressant, may alleviate depressive symptoms by increasing neurogenesis, but the potential efficacy of FXT for HFD-induced cognitive deficits is unclear. In this study, we established an obese HFD mouse model by feeding three-week-old male C57BL/6N mice with a chronic HFD for 18 weeks, then assessed adipose tissue morphology by magnetic resonance imaging and histopathology, assessed cognitive function by Morris water maze and novel object recognition tests, and detected DCX+ and BrdU+ expression in the hippocampal dentate gyrus (DG) region by immunofluorescence bioassay. Western blot detected brain-derived neurotrophic factor (BDNF) levels and CREB-BDNF pathway-related genes were assayed by Quantitative RT-PCR. The results of the study showed that HFD contributes to obesity and cognitive deficits, and more importantly, it also reduces BDNF expression and neurogenesis levels in the hippocampus. Subsequently, we found that treatment with FXT (10 mg/kg/day) ameliorated chronic HFD-induced cognitive deficits and increased the expression of Nestin, BrdU+, and DCX+ in the DG, restored BDNF expression in the hippocampus and increased the expression of genes related to CREB, BDNF, NGF, and MAPK1. In conclusion, our data elucidated that FXT ameliorates cognitive deficits and reduces chronic HFD-induced neurogenesis by restoring BDNF expression and CREB-BDNF signaling, this provides a good basis and scientific significance for future research on the clinical treatment of obesity.
Walking exercise on a treadmill for a maximum of 30 minutes with increasing speed and inclination. 3 times/week for 8 weeks.
The present invention concerns a biomarker useful in adoptive cell therapy. The biomarker in question is CDI50, otherwise termed SLAM or SLAMF1. Herein Applicants demonstrate that expression of CD 150 on tumour infiltrating lymphocytes infusion products correlates with the response rate seen in those patients. High CDI50 expression is found on patients who go on to have a complete response and low expression on patients who do not respond to therapy. The invention relates to the use of the biomarker to predict response rate or stratify patients for treatment. It also covers exploitation of this receptor in adoptive cell therapy regimens in general, including but not limited to over expression of the receptor in T-cell populations or isolation of cells expressing CD 150 in an effort to increase efficacy.
After performing the hepatectomy and verification of hemostasis, patients were randomized (external biliary duct stent or not) by sealed envelopes. Systematic intraoperative test with methylene blue or air by the external biliary duct stent (EBDS) will necessary for all patients. Intra-abdominal drainage or not and type will be at the discretion of the surgeon. The EBDS will be left open for the first 7 postoperative days and then clamped. The EBDS will be removed during a consultation 5 weeks after surgery. Both groups of patients will be reviewed at 3 months after surgery, it will be noted at this point the possible complications related to the presence of EBDS (leakage from the drain, drop..). If patients are hospitalized more than five weeks, the study will stop at their consultation three months or the day of the consultation where the DTC is removed if it is still present at 3 months.
A processor receives a selection of an image display mode via a user input device. The image display mode defines a number of medical images for display. The processor configures a surface of a touch panel user input device to define a plurality of fields. Each of the plurality of fields corresponds with a different one of the medical images. The processor receives an input, via the touch panel user input device, which selects one of the plurality of fields of the surface of the touch panel user input device and commands the processor to manipulate a medical image corresponding with the selected one of the plurality of fields. The processor manipulates at least the medical image corresponding with the selected one of the plurality of fields at one or more display devices based at least in part on the input.
The invention discloses a traditional Chinese medicine composition for treating variability measles. The traditional Chinese medicine composition comprises the following bulk drugs by weight: 4-9 parts of Platycodon grandiflorum, 10-15 parts of dandelion, 4-6 parts of Adenophora, 4-9 parts of ephedra, 5-12 parts of almond, 4-9 parts of licorice and 12-25 parts of gypsum. The traditional Chinese medicine composition is used for treating measles and can obviously reduce incidence rate of complications. The medicine provided by the invention has reliable effects of abating fever, promoting eruption, cooling diaphragm and detoxifying, and the advantages of easy material acquisition, low price convenience for manufacturing and wide scope of application. Through years of research and clinic observation on hundreds of patients, the traditional Chinese medicine composition for treating variability measles has obvious clinic treatment effect. In the treatment of measles, the medicine provided by the invention can realize stationary fever ablation, no obvious surge or drop; and from fever to normal temperature, 0.5-3 days can be saved. In addition, the medicine can turn the rash into smooth and stable state, and realizes reliable effects of promoting eruption, clearing lung, cooling diaphragm and detoxifying.
Infusion reactions to bendamustine hydrochloride have occurred commonly in clinical trials [see Adverse Reactions (6.1)]. Symptoms include fever, chills, pruritus and rash. In rare instances severe anaphylactic and anaphylactoid reactions have occurred, particularly in the second and subsequent cycles of therapy. Monitor clinically and discontinue drug for severe reactions. Ask patients about symptoms suggestive of infusion reactions after their first cycle of therapy. Patients who experience Grade 3 or worse allergic-type reactions should not be rechallenged. Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. Discontinue Bendamustine Hydrochloride Injection for patients with Grade 4 infusion reactions. Consider discontinuation for Grade 3 infusion reactions as clinically appropriate considering individual benefits, risks, and supportive care.